Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sernova Corp (TSV: SVA )

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Jun 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sernova Corp

SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
From Sinovac Biotech Ltd.
Via Business Wire
Sinovac Amends Shareholder Rights Plan
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Reports Unaudited First Half of 2021 Financial Results
From Sinovac Biotech Ltd.
Via Business Wire
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
From SINOVAC Biotech Ltd.
Via Business Wire
SINOVAC Beijing Settled Litigation of Its Business License and Seals
From SINOVAC Biotech Ltd.
Via Business Wire
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
From SINOVAC Biotech Ltd.
Via Business Wire
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
From SINOVAC Biotech Ltd.
Via Business Wire
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
From SINOVAC Biotech Ltd.
Via Business Wire
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
From SINOVAC Biotech Ltd.
Via Business Wire
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
From SINOVAC Biotech Ltd.
Via Business Wire
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
From SINOVAC Biotech Ltd.
Via Business Wire
The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
From Sinovac Biotech Ltd.
Via Business Wire
World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use
From SINOVAC Biotech Ltd.
Via Business Wire
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
From Sinovac Biotech Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.